Completed PHASE4 INTERVENTIONAL NCT00099541

Non-small Cell Lung Cancer Registry

A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis

Sponsor: Novartis Pharmaceuticals

Conditions Non-Small-Cell Lung Cancer Pleural Effusion, Malignant

Interventions zoledronic acid

Updated 6 times since 2017 Last updated: Nov 20, 2009 Started: Nov 30, 2004 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Non-Small-Cell Lung Cancer and Pleural Effusion, Malignant, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abingdon, United States , Akron, United States , Alexandria, United States , Anaheim, United States , Athens, United States , Augusta, United States , Austin, United States , Baltimore, United States , Bethlehem, United States , Birmingham, United States and 84 more locations